Intestinal Permeability in Obesity

Obesity Clinical Trial

— LEAKY GUT  

Official title:

Intestinal Permeability in Obesity of Intercellular Tight Junctions to Metabolic Complications

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02292121
• Other study ID #: P130402
• Status: Terminated
• Phase: N/A
• Start date: February 24, 2014
• Est. completion date: March 17, 2016

Study information

• Verified date: January 2021
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In rodents, obesity is associated with changes in tight junctions' structure in small intestine, which impacts intestinal permeability and results in metabolic complications. Few data exist in human. We hypothesized that intestinal permeability is altered in obese subjects in comparison to lean subjects, linked to metabolic and inflammatory status and that these alterations are modified after gastric bypass.

Description:

The regulation of the permeability of the intestinal barrier is essential in the molecular traffic between the lumen and the internal environment. It affects the absorption of nutrients and tolerance or immunization against foodborne non-self antigens that penetrate the barrier. In rodents, increased endotoxemia has been proposed as an important player in low-grade inflammation accompanying the development of obesity and metabolic disorders. In humans, the intestinal barrier function is altered in inflammatory bowel diseases (IBD, Crohn's disease, ulcerative colitis and celiac disease). The term "leaky gut" is used to describe a porous intestine with hyper-permeability associated with acute or chronic inflammatory diseases such as "systemic inflammatory response syndrome (SIRS),"acute inflammatory bowel disease (IBD for "inflammatory bowel disease").

Deficiencies of the barrier are also observed in extra-intestinal diseases (type-1 diabetes, food allergies, and autoimmune diseases). Impairments in tight junctions may precede clinical signs and constitute a risk factor for developing diseases or secondarily be altered and cause an increased entry of undesirable bacterial or nutritional antigens. The state of the intercellular tight junctions of the intestine controls the diffusion of molecules between cells. A deficiency of the intestinal barrier function is often associated with structural changes in the tight junctions resulting from loss of localization of protein or expression of genes and / or cellular signals such as ZO-1, occludin or tricellulin.

There are few studies about the condition of the intestinal barrier in the context of human obesity.

The objectives of our study are to :

• compare intestinal permeability in obese subjects with non obese subjects and after gastric bypass.

• search links between intestinal permeability and 1) metabolic and inflammatory bioclinical parameters 2) dietary profiles 3) microbiota

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 80
• Est. completion date: March 17, 2016
• Est. primary completion date: March 17, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria :

• Control subjects T1:

1. Registered for social security

2. Signed consent form

3. male or female subject between 18 and 65 years old

4. Fasting plasma triglycerides < 1.5 g/l (< 1.7 mmol/l)

5. Fasting plasma total cholesterol < 2.5 g/l (< 6 mmol/l)

6. fasting glycaemia < 5,5 mmol/l

7. BMI <25kg/m² & >18 kg/m²

8. Mean systolic blood pressure <140 mmHg and mean diastolic blood pressure < 90 mmHg.

Control subjects T2

1. Registered for social security

2. Signed consent form

3. male or female subject between 18 and 70 years old

4. IMC<25kg/m² et >18 kg/m²

5. candidate to surgery giving access to jejunal samples

Obese subjects OB:

1. Registered for social security

2. Signed consent form

3. male or female subject between 18 and 65 years old

4. Candidate to bariatric surgery (bypass) with massive (IBMI >= 40 kg/m²) or severe obesity (BMI between 35 & 40 kg/m²) with at least one obesity-related comorbidity and with a stable weight (+/-5kg) for the last 3 months, after approval by a multidisciplinary team

Exclusion criteria :

• Control subjects T1:

1. Subject with a history of vascular symptomatic disease in the last 6 months before selection.

2. Subject receiving a treatment that can affect measured parameters

3. Pregnancy

4. Subject with acute or chronic disease that can affect measured parameters or to life-threatening. Including but not limited :

1. Diabetic subjects

2. Subject with kidney disease: nephrotic syndrome, chronic renal failure

3. Subject having a gastrointestinal disorder or disease limiting intestinal absorption (celiac disease), bariatric surgery.

4. Active inflammatory disease or a history of IBD

5. Subject in a situation that, according to the investigator's opinion could interfere with an optimal participation to the study or constitute a particular risk to the subject

6. Subject in an exclusion period after participating in another clinical trial

7. Adult person subject to legal protection or unable to consent.

8. Persons deprived of their liberty by judicial or administrative decision

Control subjects T2

1. Subject with a history of symptomatic vascular disease (myocardial infarction, angina syndrome threat, surgical or endovascular surgery, stroke, lower limb arteritis symptomatic) of less than 6 months

2. Subject with any acute or chronic disease which may influence the results of the study or to life-threatening. Including but not limiting:

1. diabetic patients

2. Subject with kidney disease: nephrotic syndrome, chronic renal failure and / or serum creatinine> 1.7 times the upper limit of the reference value

3. Adult person subject to legal protection or unable to consent.

4. Persons deprived of their liberty by judicial or administrative decision

Obese subjects candidates for surgery:

1. Subject receiving treatment systemically or topically, which may interfere with the evaluation of the parameters studied (NSAIDs, antibiotics in the previous month)

2. Any disease or psychosocial context making prolonged regular monitoring impossible, which also represents a contraindication for bariatric surgery.

3. Adult person subject to legal protection or unable to consent.

4. Persons deprived of their liberty by judicial or administrative decision

Related Conditions & MeSH terms

• Body Weight
• Metabolic Diseases
• Nutrition Disorders
• Obesity

Intervention

Procedure:
• Intestinal permeability
5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.

Other:
• a solution of mannitol and lactitol

Locations

Country	Name	City	State
France	Groupe Hospitalier Pitié-Salpêtrière	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Institute of Cardiometabolism and Nutrition, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	urinary lactitol / mannitol ratio by an intestinal permeability test (IPT)	Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in obese patients before gastric bypass and 6 months after	before gastric bypass and 6 months after
Secondary	fasting zonulin serum concentrations	Measures of fasting zonulin serum concentrations in obese patients before gastric bypass and 6 months after	before gastric bypass and 6 months after
Secondary	LPS serum concentrations	Measures of LPS serum concentrations in obese patients before gastric bypass and 6 months after	before gastric bypass and 6 months after
Secondary	urinary lactitol / mannitol ratio by an intestinal permeability test (IPT)	Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in non-obese control subjects, performed twice with a one-month interval.	inclusion and after one month
Secondary	surgical samples during surgery (sub-cutaneous and visceral adipose tissue)		intraoperative